Status:
COMPLETED
Real-world Data of Nivolumab in Pre-treated NSCLC
Lead Sponsor:
Hellenic Cooperative Oncology Group
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Nivolumab is an approved treatment option for patients with previously treated advanced NSCLC, based on the survival benefit shown versus docetaxel in randomized phase III trials in second line. Howev...
Detailed Description
Patients with advanced NSCLC who had received nivolumab as 2nd line and beyond, between October 2015 and November 2019, in HeCOG clinical centres in Greece, were enrolled. Information regarding detail...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of advanced Squamous or Non-Squamous NSCLC (histologically or cytologically confirmed), who had relapsed after 1 prior platinum-based systemic treatment and who received treatment with nivolumab
- nivolumab treatment received in participating HeCOG centres between October 2015 and November 2019
- Alive patients must have signed and dated the study approved written informed consent form in accordance with regulatory and institutional guidelines, obtained before any protocol-related procedures that are not part of normal patient care.
Exclusion
- Alive patients who do not want to sign and date the study approved written informed consent form
- Patients that participated in any other clinical trial prior or after nivolumab treatment
Key Trial Info
Start Date :
October 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2020
Estimated Enrollment :
346 Patients enrolled
Trial Details
Trial ID
NCT04713462
Start Date
October 1 2015
End Date
November 1 2020
Last Update
January 19 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.